Danielle Shafer
Overview
Explore the profile of Danielle Shafer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
157
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Maher K, Shafer D, Schaar D, Bandyopadhyay D, Deng X, Wright J, et al.
Cancer Chemother Pharmacol
. 2025 Jan;
95(1):24.
PMID: 39821392
Purpose: Relapsed and/or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome continue to have a poor prognosis with limited treatment options despite advancements in rational combination and targeted therapies. Belinostat...
2.
Shafer D, Kagan A, Rudek M, Kmieciak M, Tombes M, Shrader E, et al.
Cancer Chemother Pharmacol
. 2023 Mar;
91(3):281-290.
PMID: 36864346
Purpose: Belinostat is an intravenous histone deacetylase inhibitor with approval for T-cell lymphomas. Adavosertib is a first in class oral Wee1 inhibitor. Preclinical studies of the combination demonstrated synergy in...
3.
Steimer M, Leabo J, Wang H, Heyer D, Addison N, Bowles N, et al.
JCO Oncol Pract
. 2021 Apr;
17(9):e1286-e1292.
PMID: 33793345
Purpose: The COVID-19 pandemic has posed significant challenges in the care of patients with cancer, including how to manage outpatients who are COVID-positive but do not require hospitalization. We explored...
4.
Holkova B, Shafer D, Yazbeck V, Dave S, Bose P, Tombes M, et al.
Leuk Lymphoma
. 2020 Dec;
62(5):1187-1194.
PMID: 33356689
We report the results of a phase 1 dose-escalation study of belinostat and bortezomib in adult patients with acute leukemia or MDS or CML with blast crisis. Thirty-eight patients received...
5.
Shafer D, Tombes M, Shrader E, Ryan A, Bandyopadhyay D, Dent P, et al.
Neurooncol Adv
. 2020 Jul;
2(1):vdz052.
PMID: 32642720
Background: Dimethyl fumarate (DMF), an oral agent approved for the treatment of relapsing-remitting multiple sclerosis (RRMS), has promising preclinical activity against glioblastoma (GBM). This phase I study sought to determine...
6.
Al-Juhaishi T, Khurana A, Shafer D
Best Pract Res Clin Haematol
. 2019 Apr;
32(1):47-53.
PMID: 30927975
Treatment for Hodgkin (HL) and non-Hodgkin's lymphoma (NHL) has changed dramatically in the last fifty years. While there are increasing numbers of long-term survivors, there has been increasing recognition of...
7.
Yazbeck V, Shafer D, Perkins E, Coppola D, Sokol L, Richards K, et al.
Clin Lymphoma Myeloma Leuk
. 2018 Aug;
18(9):569-575.e1.
PMID: 30122201
Background: The proteasome inhibitor bortezomib has demonstrated marked preclinical activity when combined with the histone deacetylase inhibitor vorinostat in leukemia, multiple myeloma, and mantle cell lymphoma (MCL) cells. The present...
8.
Shafer D, Grant S
Blood Rev
. 2016 Mar;
30(4):275-83.
PMID: 26972558
Acute myeloid leukemia (AML) remains a challenge to both patients and clinicians. Despite improvements in our understanding of the disease, treatment has changed minimally and outcomes remain poor for the...
9.
10.
Shafer D, Smith M, Borghaei H, Millenson M, Li T, Litwin S, et al.
Leuk Res
. 2013 Aug;
37(10):1213-5.
PMID: 23968916
Host immune responses influence follicular lymphoma (FL) outcomes. To test our hypothesis that immune cells in blood reflect that response, we assessed by peripheral blood flow cytometry in 75 untreated...